Compare PMAX & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMAX | CALC |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 63.0M |
| IPO Year | 2024 | N/A |
| Metric | PMAX | CALC |
|---|---|---|
| Price | $2.29 | $5.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | ★ 1.7M | 132.5K |
| Earning Date | 09-23-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,799,100.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.56 | $1.42 |
| 52 Week High | $24.36 | $5.34 |
| Indicator | PMAX | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 65.93 |
| Support Level | $2.30 | $4.24 |
| Resistance Level | $2.97 | $5.34 |
| Average True Range (ATR) | 0.36 | 0.41 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 37.65 | 73.24 |
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.